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ABSTRACT
Nitric oxide (NO) plays complicated roles in carcinogenesis. Endothelial nitric oxide synthase (eNOS) gene is responsible for most 
of the NO produced. For this reason, it was considered that the eNOS gene variants is associated with cancer suspectibility. The 
aim of this study was to determine whether eNOS variants (G894T and intron 4 VNTR a/b) affect in Chronic Lymphocytic Leuke-
mia (CLL) risk in Turkish patients. This is a prospective single-center crosssectional study in patients with CLL. A total of 60 CLL 
patients and 100 healthy controls with similar age and sex were included to this study. Two eNOS gene variants (G894T and 
intron 4VNTR a/b) were analysed with polymerase chain reaction (PCR) and/or restriction fragment length polymorphism (RFLP) 
methods. In this study, we found that the TT genotype of eNOS G894T variant was significantly associated with an increased 
risk in patient with CLL compared with control (OR: 0.867, Cl: 0.785-0.957, p= 0.001). There was not any significant difference in 
the eNOS G894T allele distribution between the groups (p> 0.05). In addition, no significant difference was detected between the 
CLL patients and healthy controls with respect to the frequencies of genotypes and alleles in intron 4 VNTR a/b variant of eNOS. 
eNOS gene variants (G894T and intron 4 VNTR a/b) in CLL patients were simultaneously analyzed for the first time in present 
study. Our study suggest that the eNOS G894T variant may be associated with the development of CLL in the Turkish population.
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ÖZET
Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari
Nitrik oksit (NO) karsinogenezde karışık role sahiptir. Endotelial nitrik oksit sentaz (eNOS) geni üretilen NO’un çoğundan sorumludur. Bu 
nedenle, eNOS gen varyantlarının kansere yatkınlık ile ilişkili olduğu varsayılmaktadır. Bu çalışmanın amacı kronik lenfositik lösemili (KLL) 
Türk hastalarında eNOS (G894T ve intron 4 VNTR a/b) varyantlarının risk faktörü olup olmadığı saptamaktır. Bu çalışma, KLL hastalarında 
prospektif, tek merkezli kesitsel bir çalışmadır. Bu çalışmanın amacı eNOS varyantlarının (C894T ve 4VNTR b/a) Türk hastalarda Kronik 
lenfositik lösemi (KLL) riskini etkileyip etkilemediğini saptamaktır. Bu çalışmaya 60 KLL hastası ve benzer yaş ve cinsiyette 100 sağlıklı 
kontrol dahil edilmiştir. İki eNOS gen varyantı (G894T ve intron 4VNTR a/b) polimeraz zincir reaksiyonu (PZR) ve/veya restriksiyon fragman 
uzunluk polimorfizmi (RFLP) yöntemleri ile analiz edildi. Bu çalışmada, eNOS G894T varyantı TT genotipinin KLL hastalarında kontrole 
göre belirgin şekilde artmış risk ile ilişkili olduğunu bulduk (OR: 0.867, Cl: 0.785-0.957, p= 0.001). eNOS G894T allel dağılımında gruplar 
arasında belirgin fark yoktu (p> 0.05). Ayrıca eNOS intron 4’deki VNTR a/b varyant genotip ve allel sıklığı açısından KLL hastaları ve kon-
troller arasında belirgin fark saptanmadı. Bu çalışmada KLL hastalarındaki eNOS gen varyantları (G894T ve intron 4VNTR a/b) ilk defa eş 
zamanlı olarak incelenmiştir. Sonuçlarımız eNOS G894T varyantının Türk toplumunda KLL gelişmesi ile ilişkili olabileceğini önermektedir.
Anahtar Kelimeler: Kronik lenfositik lösemi, Endotelial nitrik oksit sentaz, G894T, Intron 4 VNTR a/b
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
common adult leukemia type in the Western Eu-
ropa and North America and characterized by pro-
liferation and accumulation of morphologically 
mature CD5+/CD19+/CD23+ lymphocytes in the 
peripheral blood, bone marrow, and lymphoid tis-
sues.1,2 The precise pathogenesis of CLL is still un-
known. However genetic, environmental and im-
munological factors have been offered to account 
for the development of CLL. Patients with CLL 
represent a highly variable clinical course, with 
overall survival ranging from months to decades, 
which reflects the biological diversity of the dis-
ease.3 It was thought that there has been different 
signaling pathways associated with the onset and 
course of CLL.
Nitric oxide (NO), a free radical molecule, plays 
a crucial role in regulating cell death, angiogen-
esis, killing of tumor cells and reducing cell ad-
hesion to endothelium.4 It is considered that the 
over production of NO is related to carcinogenesis. 
Nitric oxide synthase (NOS) is the major source 
of the NO production; convertion of L-arginine 
to L-citrulline take place during NO production.5 
There are three different isoforms of NOS fam-
ily. They include neuronal-NOS (nNOS/NOS1), 
inducible-NOS (iNOS/NOS2), and endothelial-
NOS (eNOS/NOS3).6 The eNOS gene is located 
on chromosome 7 (7q36) and contains 26 exons, 
spanning 21 kilobases.4 The eNOS plays a role in 
regulation of platelet aggregation, leukocyte adher-
ence, blood pressure, and vascular smoot muscle 
cell mitogenesis and angiogenesis. The eNOS have 
various polymorphic sites. One of three functional 
variants, the G894T variant (rs1799983) is in exon 
7 and results in a Glu-Asp substitution during the 
protein synthesis. Other variant of eNOS is a func-
tional variable number tandem repeats (VNTR) (27 
bp repeat, intron 4 VNTR a/b) which causes basal 
NO production.7 Although there was several stud-
ies evaluated the impact of eNOS variants on hu-
man cancer risk, the results are stil remain unclear.
In this context, we evaluated the possible role of the 
G894T and intron 4 VNTR a/b variants of eNOS 
gene on development of CLL in Turkish patients.
PATIENTS AND METHODS
Subjects
Sixty CLL patients (35 males and 25 females) were 
diagnosed at Gaziantep University, Medical Fac-
ulty, Department of Hematology and 100 healthy 
controls (51 males and 49 females) were recruited 
in this study. Clinical characteristics, peripheral 
blood morphologies, immuno-phenotype, and 
B-lymphocytes count of higher than 5.0 x 109/L, 
confirmed the diagnosis of CLL.8 Healthy controls 
were recruited from the same geographical areas 
with patients, and they were well-matched with the 
patients group in terms of gender, age and ethnic-
ity. The control group was selected from the vol-
untaries who did not have any chronic disease. All 
participants were given detailed verbal and written 
information regarding the purpose and procedures 
of the study. This study was conducted under guide-
lines laid down in the Decleration of Helsinki, and 
all procedures involving human subjects were ap-
proved by Local Ethics Committee (07-2007/40).
Genotyping Analysis
About 5 mL peripheral blood was collected by 
venipuncture using Vacutainer tubes with EDTA as 
anticoagulant for the analysis of eNOS gene vari-
anst. DNA extracted from leukocytes according to 
the established protocol.9 Two eNOS gene variants 
(G894T and intron 4 VNTR a/b) were determined 
by polymerase chain reaction (PCR) and/or restric-
tion fragment length polymorphism (RFLP) as 
described by Safarinejad et al.10 The G894T vari-
ant was determined by PCR using the following 
primers 5’-CATGAGGCTCAGCCCCAGAAC-3’ 
(forward) and 5’-AGTCAATCCCTTTGGTGCT-
CAC-3 (reverse). PCR products were digested by 
MboI enzyme (Invitrogen, Carlsbad, CA, USA) at 
37oC for overnight. Then, fragments were seper-
ated on 3% agarose gel electrophoresis and visual-
ized using ultraviolet light. The 206 bp products 
had a consistent restriction site resulting in a 119 bp 
and an 87bp fragment. The 27 bp-VNTR a/b geno-
type in intron 4 of eNOS were evaluated by PCR 
amplification using primers 5’-AGGCCCTATG-
GTAGTGCCTTT-3’ (forward) and 5’-TCTCT-
TAGTGCTGTGGTCAC-3’ (reverse).10 The am-
plified products were seperated by electrophoresis 
on a 2% agarose gel and visualized by ethidium 
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bromide staining. The wild type allele contained 
five tandem repeats of 27 bp and 420 bp and the 
mutant allele four tandem repeats of 27 bp and 393 
bp band. 
Statistical Analysis
All data were analyzed using software SPSS ver-
sion 14.0 for Windows (SPSS Inc., Chicago, IL; 
USA). The statistical significance of the differenc-
es between the patient and control groups was es-
timated by logistic regression analysis. Odds ratio 
(OR) and 95% confidence interval (CI) were also 
calculated. Differences in eNOS genotype frequen-
cies between the patient and control groups were 
compared with chi-square test and, Fisher’s exact 
test was used when needed. All analyses were two-
tailed, and differences were interpreted as statisti-
cally significant when p< 0.05.
RESULTS
In the present study, a total of 160 subjects, includ-
ing 60 CLL patients and 100 adult healthy con-
trols were genotyped for the G894T and intron 4 
VNTR4 a/b variants of eNOS gene. There were 25 
(41.6%) women and 35 (58.4%) men in the patient 
group and 49 (49%) women and 51 (51%) men 
in the control group. The genotype distributions 
and allele frequencies of eNOS G894T and intron 
4VNTR a/b variants among the patients and con-
trols are shown in Table 1. 
The prevalence of genotypes of AA, AB, and BB 
profiles for eNOS intron 4 VNTR variant were 
63.3%, 26.7% and 10% respectively in patients 
with CLL, and 72%, 25% and 3% respectively 
in control group. No significant differences were 
observed between groups for the eNOS intron 4 
VNTR genotype and allele frequencies.
For the G894T variant of the eNOS gene, in the 
CLL group 34 patients (56.7%) were GG geno-
type, 18 patients (30%) were GT genotype, and 
8 patients (13.3%) were TT genotype; in the con-
trol group, 65 healthy individuals (65%) were GG 
genotype, 35 individuals (35%) were GT geno-
type, and 0 individuals (0%) were TT genotype. 
The genotype distribution of eNOS G894T variant 
was showed statistically significant difference be-
tween the patients and the controls. We found that 
the TT genotype of eNOS G894T variant was sig-
nificantly associated with an increased risk in pa-
tient with CLL compared with healthy control (p= 
0.001, OR:0.867, Cl: 0.785-0.957). There was not 
any significant difference in the eNOS G894T al-
lele distribution between the patients and controls 
(p> 0.05). 
DISCUSSION
CLL is a rather heterogenous malignant disease 
in terms of clinical presentation, and response to 
treatment, and remains untreatable with conven-
Table 1. Genotype and allele distribution of eNOS gene variants in CLL patients and control subjects.
  CLL Control OR 95%Cl p
  na (%)  nb (%) 
eNOS (4a/b) Genotype     
 AA 38 (63.3)  72 (72) 0.672 0.339-1.330 0.292
 AB 16 (26.7)  25 (25)        0.917 0.442-1.901 0.853
 BB 6 (10.0)  3 (3.0) 0.278 0.067-1.158 0.081
 Allele     
 A 92 (76.7)  129 (64.5)   
 B 28 (23.3)  31 (35.5) 0.596 0.337-1.055 0.100
eNOS(G894T) Genotype     
 GG 34 (56.7)  65 (65.0) 0.808 0.417-1.563 0.612
 GT 18 (30.0)  35 (35.0) 1.256 0.631-2.501 0.604
 TT 8 (13.3)  0 (-) 0.867 0.785-0.957 0.001
 Allele     
 G 86 (71.6)  165 (82.5)   
 T 34 (28.3)  45 (17.5) 0726 0.432-1.218 0.230
OR: Odds Ratio; Cl: Confidence Intervals; an: 60, bn: 100, Adjusted by age and gender
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tional chemotherapy.11 The data indicate that a 
strong family and genetic factors contribute to the 
etiology of CLL.12
NO, an important messenger molecule, is involved 
several physiologic and patho-physiologic pro-
cesses such as neurotransmission, smooth muscle 
relaxation, immunity, vasodilatation, and carcino-
genesis.13 In previous studies, it was reported that 
over production of NO can cause DNA damage 
and inhibits DNA repair mechanism.14,15 Howev-
er, in some other studies it was reported that NO 
can increase the activity of DNAPKCs (the cata-
lytic subunit of the DNA-dependent protein kinase 
complex), thus preventing DNA damage; further-
more, it may enhance blood flow, destroy tumor 
cells, diminish tumor cell adhesion to endothelium 
and regulate apoptosis.16-19 In animal experients, 
also it was shown that NO has anti-tumor effects 
produced by the immune-defense system.20
Since NO production can be affected by eNOS 
gene, eNOS gene variants have been studied in 
carcinogenesis. It has been shown that eNOS gene 
can modulate cancer-related events such as angio-
genesis, invasion, and metastasis.21 Recent studies 
suggest that the expression of eNOS is not restrict-
ed to normal tissues, and it is also widely expressed 
in tumor tissues, adjusting endothelial cell damage 
and mobilization and homing of bone marrow en-
dothelial progenitor cells, and participating in the 
formation of blood vessels through NO generation, 
which can have an impact on the growt hand me-
tastasis of tumors.22
Angiogenesis is involved in solid tumor growth, 
progression and metastasis. Evidence supports 
that the progression of hematolymphoid malignan-
cies depend on the formation of new blood ves-
sel. Vascular endothelial factor (VEGF) is the main 
proangiogenic agent that stimulates receptors on 
vascular endothelial cells and induces new blood 
vessel formation.23 eNOS has a central mediator 
role in VEGF-induced angiogenesis and vascular 
permeability.24 Demacq et al. reported that VEGF 
and eNOS gene variants are associated with high 
risk of relapse in childhood with acute lymphoblas-
tic leukemia (ALL).25 Almost 400 eNOS variants 
have been described up to now and it was found 
that some of them to be related to carcinogenesis.5 
It was reported that some of these variants are sig-
nificantly related with the development of certain 
cancer types.26,27
This case-control study examined the G894T and 
intron 4 a/b variants of eNOS gene and their re-
lationship to suspectibility for CLL in a Turkish 
cohort. Although association of the eNOS vari-
ants with several solid tumors has been previously 
shown, as yet, there is no study in literature about 
the association of this eNOS variants with hema-
tologic diseases. To our knowledge, this is the first 
study to evaluate the eNOS variants in relation to 
CLL risk in a Turkish cohort.
VNTR variant in intron 4 of eNOS gene accounts 
for >25% of basal plasma NO generation.10 There 
have been existed two alleles in intron 4 of the 
eNOS gene. While the larger allele consists of five 
tandem repeat 27-bp repeats, small allele has four 
repeats.28 It was reported that carriers of the 4a al-
lele had lower NO levels than 4b/4b homozygous 
subjects.29 The impact of 4 a/b variant of the eNOS 
gene is still unclear, it has been declared that this 
variant would regulate the expression of the eNOS 
gene by the editing of small RNAs (siRNAs).30 
Phenotypic significance of the eNOS intron 4 a/b 
variant was evaluated in various conditions in pre-
vious studies.31-33 It was found that 4a allele is asso-
ciated with coronary artery disease, stroke, and re-
nal disease.34-36 In studies for cancer suspectibility, 
it was found that eNOS 4 a/b variant is associated 
with colorectal cancer, prostate cancer, whereas 
there was no significant association with bladder 
cancer and overall cancers.4,7,10,37,38 In sub-group 
analysis based on ethnicity of meta analysis, it was 
reported that the eNOS 4 a/b variant was associat-
ed with an increased risk of cancer in Caucasians.24 
In our study, we found that the the eNOS intron 4 
a/b variant wasn’t significantly different between 
patients and controls. 
Effects of the eNOS G894T variant on cancer risk 
and progression have been investigated by several 
researchers and findings of these studies have been 
heterogeneous and sometimes contradictory. Al-
though, there were studies that the eNOS G894T 
variant was associated with prostate cancer, blad-
der cancer, colorectal cancer, larynx cancer, there 
were studies that the eNOS G894T variant was not 
associated with cancer and survival.4,5,7,39-42 Lee et 
al. declared that there was no significant associa-
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tion between the eNOS G894T variant and breast 
cancer, but this variant was associated with lymph 
node involvement.43
In present study, we found a significant difference 
in genotype distribution between patients and con-
trols. We found that TT genotype of eNOS G894T 
was significantly higher in patients with CLL com-
pared with controls (p= 0.001). 
Case-control association studies represent an im-
portant tool for understanding the role that genes 
play in the carcinogenesis. The limitations of this 
study should also be noted. First, we focused on 
only two variants involved in the pathway of eNOS, 
other regulatory genes in the NOS family signal-
ling pathway may also contribute to the pathogen-
esis of CLL. Second, owing to the relatively small 
sample size, the frequencies of some homozygous 
variants were low in groups and therefore reduced 
the statistical power. Finally, lack of assessment of 
expression levels of eNOS is also a limitation of 
this study. 
CONCLUSIONS
Although findings with respect to the role of eNOS 
gene variants in cancer pathogenesis are contflict-
ing, the difference between data may be explained 
in view of the genetic variability of populations. 
This study did not reveal significant association 
between eNOS intron 4 VNTR variant and CLL, 
however we represented the first result on eNOS 
G894T variant and CLL in a Turkish cohort. Large-
scale studies should be replicated with different 
subjects and/or other ethnic groups to fully eluci-
date the effects of these variants on susceptibility 
to CLL.
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